Abstract Background Chronic stress is a key risk factor for major depressive disorder (MDD), one of the leading causes of disability worldwide1. Despite available pharmacological therapies, treatment-resistant depression (TRD) remains a clinical challenge. Hallucinogens such as ketamine and serotonergic psychedelics including psilocybin and lysergic acid diethylamide (LSD)2 show rapid...
Abstract Background Alcohol use disorder (AUD) presents significant health and societal issues. The disorder is characterized by locomotor impairments and disruption of the dopaminergic neurotransmission in the ventral tegmental area (VTA). Current AUD treatments are limited, necessitating the exploration of novel drugs. The potential therapeutic use of psychedelics, particularly lysergic acid...